Enzo Biochem. has filed a patent for methods and compositions using sphingosine kinase-1 inhibitors and sphingosine-1-phosphate receptor agonists to treat cancers and myeloproliferative disorders. Claim 1 specifically focuses on treating prostate cancer by administering ozanimod to a mammalian subject. GlobalData’s report on Enzo Biochem gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Enzo Biochem Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Enzo Biochem, Cancer treatment biomarkers was a key innovation area identified from patents. Enzo Biochem's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of prostate cancer using ozanimod

Source: United States Patent and Trademark Office (USPTO). Credit: Enzo Biochem Inc

A recently filed patent (Publication Number: US20240024259A1) discloses a method for treating prostate cancer in mammalian subjects by administering ozanimod or its pharmaceutically acceptable salt. The method involves administering an effective amount of ozanimod or its salt to a mammalian subject in need of treatment for prostate cancer. Additionally, the patent specifies that the hydrochloride salt of ozanimod can be specifically administered to the mammalian subject, with a particular emphasis on human subjects.

Furthermore, the patent claims highlight the specific application of the method for treating prostate cancer in human subjects by administering the hydrochloride salt of ozanimod. This targeted approach underscores the potential efficacy of ozanimod or its salt in combating prostate cancer in humans. By focusing on the administration of the hydrochloride salt of ozanimod, the patent aims to provide a precise and effective treatment option for individuals suffering from prostate cancer. Overall, the patent's claims offer a promising method for addressing prostate cancer in mammalian subjects, particularly in the context of human patients, through the use of ozanimod or its pharmaceutically acceptable salt.

To know more about GlobalData’s detailed insights on Enzo Biochem, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies